Skip to main content

ADVERTISEMENT

biomarkers

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
Videos
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
Research Reports
08/22/2018
Alexandra Christodoulopoulou, MSc
Bruce A Bach, MD, PhD
Andrew J Klink, PhD, MPH
Guy Hechmati, MD, MSc
Urvi Mujumdar, MPH
Bruce A Feinberg, DO
Marwan Fakih, MD
Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...
Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...
...
08/22/2018
Journal of Clinical Pathways
Quiz
11/03/2016
JCP Editors
While previously reported as a promising biomarker for bladder cancer, a recent study published in Cancer found that which of the following was not a reliable predictor of cancer progression or treatment...
While previously reported as a promising biomarker for bladder cancer, a recent study published in Cancer found that which of the following was not a reliable predictor of cancer progression or treatment...
...
11/03/2016
Journal of Clinical Pathways
10/27/2016
JCP Editors
Tumor cells collected during the removal of a cancerous bladder may help clinicians better identify high-risk cancers, determine prognosis, refine their use of biomarkers, and provide more personalized care,...
Tumor cells collected during the removal of a cancerous bladder may help clinicians better identify high-risk cancers, determine prognosis, refine their use of biomarkers, and provide more personalized care,...
Tumor...
10/27/2016
Journal of Clinical Pathways
Research in Review
10/12/2016
JCP Editors
Serum microRNA-206 (miRNA) may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence, according to a study published in Cellular Physiology and...
Serum microRNA-206 (miRNA) may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence, according to a study published in Cellular Physiology and...
Serum...
10/12/2016
Journal of Clinical Pathways
Department
09/17/2016
JCP Editors
Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the inaugural Clinical Pathways Congress with a discussion on the relationship between...
Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the inaugural Clinical Pathways Congress with a discussion on the relationship between...
...
09/17/2016
Journal of Clinical Pathways
Research in Review
09/09/2016
JCP Editors
In a new study, researchers identified 14 centromere and kinetochore (CEN/KT) genes regulating genome integrity that were consistently overexpressed in a variety of cancers. This allowed the researchers to create the...
In a new study, researchers identified 14 centromere and kinetochore (CEN/KT) genes regulating genome integrity that were consistently overexpressed in a variety of cancers. This allowed the researchers to create the...
In a...
09/09/2016
Journal of Clinical Pathways
Research in Review
09/01/2016
JCP Editors
Adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment may be used to predict patient response to melanoma immunotherapy, according to a study published in Cancer...
Adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment may be used to predict patient response to melanoma immunotherapy, according to a study published in Cancer...
...
09/01/2016
Journal of Clinical Pathways
Quiz
08/25/2016
JCP Editors
A study published in Science Translational Medicine found that the inhabitation of what oncogenic protein might possibly be a target for therapeutic benefit in patients with non-small cell lung...
A study published in Science Translational Medicine found that the inhabitation of what oncogenic protein might possibly be a target for therapeutic benefit in patients with non-small cell lung...
A...
08/25/2016
Journal of Clinical Pathways
Research in Review
08/22/2016
JCP Editors
Inhibition of oncogenic protein BMI1 may offer a therapeutic benefit for certain patients with lung cancer, according to the results of an analysis published in Science Translational Medicine. In a prior study,...
Inhibition of oncogenic protein BMI1 may offer a therapeutic benefit for certain patients with lung cancer, according to the results of an analysis published in Science Translational Medicine. In a prior study,...
...
08/22/2016
Journal of Clinical Pathways